GE licenses fetal heart image acquisition method

GE Healthcare has licensed a technique patented by an Eastern Virginia Medical School (EVMS) obstetrician that can automate the acquisition of ultrasound images used by physicians to diagnose fetal heart defects.

Alfred Abuhamad, MD, chairman of obstetrics and gynecology at EVMS developed the automation protocol, called Sonography-based volume computer-aided diagnosis (SonoVCAD).

GE said it has incorporated Abuhamad’s automation protocol in the Voluson E8, the new version of its GE Voluson ultrasound platform for women’s healthcare. The new 3D/4D ultrasound system includes a number of new tools to help improve clinical workflow, including SonoVCAD, according to the company.

According to the American Heart Association, congenital heart defects rank as the most common birth defect and the number one cause of death during the first year of life. Each year in the Unites States, twice as many children die from congenital heart disease as die from all forms of childhood cancers combined.

Around the web

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.